Nordic Nanovector Starting Pivotal Trial With Lead Asset Betalutin In R/R FL
Executive Summary
Norwegian biotech is starting PARADIGME Phase IIb trial testing Betalutin in follicular lymphoma.
You may also be interested in...
Nordic Nanovector To Restructure After Discontinuing Lymphoma Trial
The company still sees a potential future for Betalutin and hopes to partner the asset as it looks to focus on the rest of its pipeline.
Appointments: Nordic Nanovector Loses CEO, Verona Pharma Loses CMO, Plus New CEOs At DalCor And PureTech Health
This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.